Table 4.
Outcome | Percentage at 36 months | ||||
---|---|---|---|---|---|
EFS | TFS | FFS | OS | ||
Overall | 86 | 93 | 71 | 89 | |
Imatinib | 91 | 96 | 70 | 87 | |
2GTKI | 78 | 90 | 73 | 95 | |
12-months | CCyR | 96 | 100 | 88 | 100 |
No CCyR | 75 | 100 | 75 | 100 | |
18-months | MMR | 100 | 100 | 90 | 100 |
No MMR | 75 | 100 | 75 | 100 |
CCyR, Complete Cytogenetic Response; MMR, Major Molecular Response; 2GTKI, Second Generation tyrosine kinase inhibitor; EFS, Event Free Survival; TFS, Transformation Free Survival; FFS, Failure Free Survival; OS, Overall Survival